Skip to main content
Equibles
IONS logo

IONS · Ionis Pharmaceuticals Inc · Metrics

Track IONS — free

Use IONS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IONS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$45.40 +1.02 (+2.30%) At close · Oct 20
Russell 1000 member Rebalance outlook locked
Market Cap
$7.54B
Shares
166.18M
Volume · Oct 20 2.49M Avg daily vol (3M) 3.28M

IONS metrics

84 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$45.40
Market cap
$7.54B

Price action

20 metrics
Price change (1W)
+7.1%
Price change (30D)
+1.1%
Price change (3M)
-15.0%
Price change (6M)
-39.3%
Price change (YTD)
-42.6%
Price change (1Y)
-38.3%
Trailing year
Price change (5Y)
+48.8%
52-week high
$86.50
52-week low
$42.38
Change from 52-week high
-47.5%
Change from 52-week low
+7.1%
Annualized volatility
42.6%
Annualized volatility (3M)
43.6%
Beta
0.6
RSI (14D)
47.2
Price vs SMA 50
-11.4%
Price vs SMA 200
-33.5%
Avg volume (3M)
3.28M
Relative volume
0.8
Average dollar volume
$167.43M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
166.18M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.4×
reciprocal yield 13.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.4×
reciprocal yield 11.9%
P / book
16.8
reciprocal yield 6.0%
FCF yield
-7.6%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.7%

Historical valuation

8 metrics
P / E historical average (3Y)
60.3×
reciprocal yield 1.7%
P / E historical average (5Y)
60.3×
reciprocal yield 1.7%
EV / revenue historical average (3Y)
8.1×
reciprocal yield 12.4%
EV / revenue historical average (5Y)
8.0×
reciprocal yield 12.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
98.2%
Operating margin
-68.0%
Trailing 12 months
Net margin
-64.7%
Gross profit (TTM)
$858.07M
Operating profit (TTM)
−$594.36M
Net income (TTM)
−$565.17M
Trailing 12 months
Diluted EPS (TTM)
$-3.46
FCF margin
-64.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.57
Stock compensation per diluted share (TTM)
—
Book value per share
$2.99

Growth

11 metrics
Revenue growth YoY
-40.7%
Year over year
Net income growth YoY
-192.8%
Revenue (TTM)
$874.09M
Trailing 12 months
EPS growth YoY
-198.6%
Shares change YoY
-9.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+17.1%
Revenue CAGR (5Y)
+5.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-128.5%
Return on assets
-18.9%
Debt / equity
3.6
Current ratio
7.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$560.84M
Quick ratio
7.7
Interest coverage
-31.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$917.32M
Latest balance sheet
Cash & equivalents
$350.06M
Total assets
$2.99B
Total debt
$1.76B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$496.43M
Capital expenditures (TTM)
$64.41M
R&D (TTM)
$173.70M
SG&A (TTM)
$527.75M
Stock compensation (TTM)
$163.34M
R&D / revenue
—
Stock compensation / revenue
18.7%

Ownership (13F)

9 metrics
13F filers
523
13F filer change QoQ
+21
Institutional ownership
112.5%
Conviction holders (share of 13F filers)
1.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.0%
Holder tenure
15.7
Price vs estimated holder cost
+36.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.9%

Short interest

3 metrics
Short interest
13.5%
Latest settlement · 4.6 days to cover
Days to cover
4.6d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
$997,311
Insider-sentiment score
73 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 874015 CUSIP 462222100 13F (30d) 47 filings 46 filers Visit website Investor relations